|
Arthur joined Gilde Healthcare Partners in 2001. He became investment manager in 2005 and partner in 2006. He has been involved in numerous investments and divestments including Ablynx, Agendia, AMT, BG Medicine, IDEA, Neuro3D and Pieris. Arthur led the investments in the US-based companies Conatus Pharmaceuticals and FlowCardia. Arthur serves on the board of FlowCardia and observed on the boards of Agendia and Amsterdam Molecular Therapeutics. Prior to joining Gilde, Arthur was involved in cardiovascular research at TNO in the Netherlands where he focused research on atherogenesis and the role of apoptosis in plaque stability. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He specialized in molecular toxicology at the departments of Toxicology and Biopharmacy of the Leiden/Amsterdam Center for Drug Research. He is a Dutch national. | 